M&A Activity Slows in 2022 as the Pandemic Biotech Boom Fades
IQVIA Pharma Deals
December 2022
Lucy Haggerty, IQVIA Pharma Deals
Taskin Ahmed, IQVIA Pharma Deals
 |
After rebounding in 2021 following the challenges caused by the COVID-19 pandemic, M&A dealmaking took a surprising turn in the first half of 2022 with a significant decline in activity, both in terms of deal volume and value, amid challenging market conditions and escalating geopolitical tensions. | This reduced appetite for M&A continued into Q3 2022 as ongoing uncertainties led risk-averse pharmaceutical companies to enter smaller scale, asset-driven acquisitions opposed to big-ticket transformational buyouts. |
To read more, please fill out this form to download the article
Learn more about IQVIA Pharma Deals and find more insights here.
Copyright © 2026 IQVIA Holdings Inc. and its affiliates. All rights reserved. Privacy Statement
